This is a significant regulatory catalyst for a $10M market cap biotech. The PMDA support de-risks the Japan approval pathway and provides a clear timeline to submission in Q4 2026. Monitor for any financing needs ahead of submission and post-market study costs.
Price Chart
Executive Summary
BioCardia announced that Japan's PMDA Consultation Record supports submission for regulatory approval of CardiAMP cell therapy for ischemic HFrEF, with submission anticipated in Q4 2026. The PMDA confirmed alignment on remaining questions and noted trial outcomes were credible, estimating 20,000 of 300,000 Japanese HFrEF patients would initially be eligible.
Key Facts
- PMDA Consultation Record supports regulatory submission for CardiAMP cell therapy in ischemic HFrEF
- Submission anticipated in Q4 2026, timeline of 7 months from May 28, 2026
- PMDA noted positive trial outcomes were credible
- Estimated 20,000 of 300,000 HFrEF patients in Japan initially eligible
- CardiAMP Cell Therapy has FDA Breakthrough designation
- Clinical data showed increased exercise tolerance by avg 179 seconds at 2 years, angina episodes reduced by avg 82% at 6 months
- No treatment emergent major adverse cardiac events reported
Financial Impact
No financial figures provided; regulatory milestone with potential to unlock Japan market for CardiAMP therapy
Risk Factors
- PMDA review process is rigorous and approval is not guaranteed
- Company's liquidity position and ability to fund submission and post-market study
- Japan market opportunity (20K patients) is modest relative to development costs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001437749-26-018670 |
| Exhibit: ex_969199.htm | 0001437749-26-018670 |
| Document: 0001437749-26-018670-index-headers.html | 0001437749-26-018670 |
| Document: 0001437749-26-018670-index.html | 0001437749-26-018670 |
| Document: 0001437749-26-018670.txt | 0001437749-26-018670 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 8d ago | 8-K | $0.8975 $1.04 | ▲ +15.88% | ▲ +15.54% | $0.9000 (+0.28%) |
Oct 19, 2026 8d ago | Press Release | $0.9000 $1.04 | ▲ +15.56% | ▲ +15.22% | $0.9000 (−0.00%) |
Oct 7, 2026 20d ago | 8-K | $1.09 $1.06 | ▼ −2.75% | ▼ −2.33% | $0.9000 (−17.43%) |
Oct 1, 2026 26d ago | 8-K | $1.02 $1.04 | ▲ +1.96% | ▲ +1.22% | $0.9000 (−11.76%) |
Oct 1, 2026 26d ago | Press Release | $1.02 $1.04 | ▲ +1.96% | ▲ +1.22% | $0.9000 (−11.76%) |
Sep 23, 2026 4w ago | 8-K | $1.05 $1.07 | ▲ +1.90% | ▲ +1.99% | $0.9000 (−14.29%) |
Sep 23, 2026 4w ago | Press Release | $1.05 $1.07 | ▲ +1.90% | ▲ +1.99% | $0.9000 (−14.29%) |
Sep 10, 2026 6w ago | 8-K | $1.10 $1.08 | ▼ −1.82% | ▼ −2.67% | $0.9000 (−18.18%) |
Aug 24, 2026 9w ago | 8-K | $1.06 $1.13 | ▲ +6.60% | ▲ +6.28% | $0.9000 (−15.09%) |
Aug 5, 2026 11w ago | Press Release | $0.9500 $0.9496 | ▼ −0.04% | ▲ +0.12% | $0.9000 (−5.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers